This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hideshima, T. Articles by Anderson, K. C. Search for Related Content PubMed PubMed Citation Articles by Hideshima, T. Articles by Anderson, K. C.

Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma

Teru Hideshima, Dharminder Chauhan, Paul Richardson, Kenneth C. Anderson

From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Address reprint requests to Kenneth C. Anderson, MD, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: kenneth_anderson{at}dfci.harvard.edu.

In vitro and in vivo models have been developed that have allowed for delineation of mechanisms of multiple myeloma (MM) cell homing to bone marrow (BM); tumor cell adhesion to extracellular matrix proteins and BM stromal cells; and cytokine-mediated growth, survival, drug resistance, and migration within the BM milieu. Delineation of the signaling cascades mediating these sequelae has identified multiple novel therapeutic targets in the tumor cell and its BM microenvironment. Importantly, novel therapies targeting the tumor cell and the BM, as well as those targeting the tumor cell or BM alone, can overcome the growth, survival, conventional drug resistance, and migration of MM cells bound to BM using both in vitro and in vivo severe combined immunodeficiency mouse models of human MM. These studies have translated rapidly from the bench to the bedside in derived clinical trials, and have already led to the United States Food and Drug Administration approval of the novel proteasome inhibitor bortezomib for treatment of relapsed/refractory MM. Novel agents will need to be combined to enhance cytotoxicity, avoid development of drug resistance, and allow for use of lower doses in combination therapies. Genomics, proteomics, and cell signaling studies have helped to identify in vivo mechanisms of sensitivity versus resistance to novel therapies, as well as aiding in the rational application of combination therapies. These studies have therefore provided the framework for a new treatment paradigm targeting the MM cell in its BM milieu to overcome drug resistance and improve patient outcome in MM.

Supported by National Institutes of Health Grants No. SPORE IP50 CA10070-01, PO-1 78378, and RO-1 CA 50947 Grants; the Doris Duke Distinguished Clinical Research Scientist Award (K.C.A.); the Multiple Myeloma Research Foundation (T.H., D.C.); and the Cure for Myeloma Research Fund (K.C.A.).

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				J. S. Carew, S. T. Nawrocki, V. K. Reddy, D. Bush, J. E. Rehg, A. Goodwin, J. A. Houghton, R. A. Casero Jr, L. J. Marton, and J. L. Cleveland The Novel Polyamine Analogue CGC-11093 Enhances the Antimyeloma Activity of Bortezomib Cancer Res., June 15, 2008; 68(12): 4783 - 4790. [Abstract] [Full Text] [PDF]

				M. Mimeault and S. K. Batra Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies Ann. Onc., October 1, 2007; 18(10): 1605 - 1619. [Abstract] [Full Text] [PDF]

				J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF]

				P. Ame-Thomas, H. Maby-El Hajjami, C. Monvoisin, R. Jean, D. Monnier, S. Caulet-Maugendre, T. Guillaudeux, T. Lamy, T. Fest, and K. Tarte Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis Blood, January 15, 2007; 109(2): 693 - 702. [Abstract] [Full Text] [PDF]

				L. Agnelli, S. Bicciato, S. Fabris, L. Baldini, F. Morabito, D. Intini, D. Verdelli, A. Callegaro, F. Bertoni, G. Lambertenghi-Deliliers, et al. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma Haematologica, January 1, 2007; 92(1): 56 - 65. [Abstract] [Full Text] [PDF]

				W. Dalton and K. C. Anderson Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma. Clin. Cancer Res., November 15, 2006; 12(22): 6603 - 6610. [Abstract] [Full Text] [PDF]

				X. Xin, T. J. Abrams, P. W. Hollenbach, K. G. Rendahl, Y. Tang, Y. A. Oei, M. G. Embry, D. E. Swinarski, E. N. Garrett, N. K. Pryer, et al. CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3-Expressing Orthotopic Multiple Myeloma Model in Mice. Clin. Cancer Res., August 15, 2006; 12(16): 4908 - 4915. [Abstract] [Full Text] [PDF]

				M. Cavo Myeloma therapy: the future is bright Blood, December 15, 2005; 106(13): 4018 - 4019. [Full Text] [PDF]